Morphoceuticals Announces Roger Pomerantz, MD, as Chairman of its Board of Directors
MEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Morphoceuticals Inc., a TechBio company pioneering AI-guided electroceuticals for tissue repair and organ regeneration, today announced the appointment of industry veteran Roger Pomerantz, MD, as Chairman of its Board of Directors. Pomerantz joins as an independent director. The company is advancing a novel technology platform, based on the first ever atlas of the bioelectrome - the electrical networks by which cells communicate throughout the body, powered by the movement of ions creating voltage patterns. These electrical networks enable cells to work together to take shape into tissues and organs and allow for previously unexplored therapeutic strategies based on tissue repair and organ regeneration.
Pomerantz has led the development of 14 large and small molecule therapies, and a breakthrough microbiome therapeutic, that have all won FDA approval. He currently serves on the Boards of Directors for multiple life sciences companies, including Enlivex Therapeutics, Indaptus Therapeutics, 1E Therapeutics and CollPlant. He was the President, CEO and Chairman of Seres Therapeutics, the first publicly traded microbiome therapeutics company. Pomerantz held senior roles at multiple pharmaceutical companies, including as the Global Head of Infectious Disease at Johnson & Johnson and Head of Licensing and Acquisitions at Merck. He holds a BA in Biochemistry and an MD, both from The Johns Hopkins University.
'Morphoceuticals is building a platform that has the potential to transform human health,' said Pomerantz. 'I am proud to become the Chairman of its Board of Directors and collaborate with a first-rate team toward development of a tool with such enormous power.'
'It is a great honor to bring Roger into our company as we near completion of the toolkit necessary to build the first ever atlas of the bioelectrome,' said Jim Jenson, PhD, CEO of Morphoceuticals. 'With his expert guidance, and the extraordinary foundation laid by Drs. Michael Levin and David Kaplan, we can harness the power of non-neural bioelectric circuits that guide re-growth in the body into a platform technology that can address some of the most intractable healthcare challenges.'
Morphoceuticals is building on the groundbreaking work of its co-founders, Michael Levin, Vannevar Bush Professor of Biology in the School of Arts and Sciences, and David Kaplan, Stern Family Endowed Professor of Engineering in the School of Engineering, both of Tufts University, who successfully demonstrated limb regeneration in an African clawed frog, becoming the first to achieve functional limb regeneration in an adult animal of a species that does not naturally regenerate complex limbs in adulthood.
The company has secured more than $15 million in seed financings, initially led by Juvenescence and Prime Movers Lab.
ABOUT MORPHOCEUTICALS Morphoceuticals is a TechBio company focused on understanding and manipulating the bioelectrome to induce regeneration and treat disease. The bioelectrome is the set of electrical communication networks within the body that bind multi-cellular collectives together for a common purpose, maintaining tissue and organ level integrity and health. We are building an atlas of the bioelectrome using our world-first suite of model systems and proprietary AI techniques. By understanding and manipulating these networks, we aim to rewrite them for the treatment of conditions that are inadequately addressed by existing therapeutic strategies. At Morphoceuticals, we are reprogramming the software of life. For more information visit www.morphoceuticals.com
Media Contact Michael FalconePearl Street Partnersmichael@pearlst.com617-990-6712
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/08bfec7a-ddc5-4597-8ed6-75eaca516d69
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Falling Prices, NVMe Adoption, and Demand for High-Capacity, High-Speed Storage in Data-Driven Industries Fueling Expansion
The SSD market is projected to grow from USD 35.545 billion in 2025 to USD 72.657 billion in 2030, driven by performance enhancements and declining prices. NVMe tech boosts SSD speed, meeting cloud and data center needs. North America leads, while Asia Pacific sees rapid growth due to IT expansion. Solid State Drive Market Dublin, July 29, 2025 (GLOBE NEWSWIRE) -- The "Solid State Drive Market - Forecasts from 2025 to 2030" report has been added to solid-state drive market is expected to grow from USD 35.545 billion in 2025 to USD 72.657 billion in 2030, at a CAGR of 15.37%.The SSD market is propelled by declining prices, making these drives more accessible across industries. The adoption of Non-Volatile Memory Express (NVMe) technology has significantly improved SSD performance, offering faster data transfer rates and reduced latency. These advancements cater to the growing needs of cloud customers and data centers, where high-speed, reliable storage is critical. Additionally, SSDs' advantages - such as lower power and space consumption, resistance to physical shocks, and faster boot times - further drive their adoption. The development of high-capacity SSDs presents significant growth potential. These drives meet the escalating storage demands of industries handling large datasets, such as life sciences and financial services. The push for denser storage solutions supports complex operations, positioning SSDs as a cornerstone of modern data management and fueling market expansion over the forecast period. Market Segmentation By Interface TypeThe SSD market is segmented by interface type into SATA, SAS, Fibre Channel, and ATA/IDE. The SATA interface dominates due to its lower cost, smaller cable size, and efficient data transfer via higher signaling rates and I/O queuing protocols. SATA's compatibility with older desktop PCs upgrading from HDDs, combined with its affordability compared to other interfaces, ensures its significant market share. SAS drives, offering varied endurance options to match specific workloads, are also gaining traction in enterprise End-User IndustryBy end-user industry, the market is divided into automotive, aerospace and defense, medical, consumer electronics, and others. The automotive sector holds a substantial share due to the integration of advanced technologies in vehicles, requiring reliable storage for data-intensive systems. Consumer electronics also command a significant share, driven by the miniaturization of devices and the industry's focus on efficient, high-performance storage Outlook North America: Market LeaderNorth America is projected to hold the largest market share, driven by advanced storage solutions and substantial enterprise spending on IT infrastructure. Companies in the region prioritize SSDs to enhance business productivity and maintain competitive advantages, particularly in data centers and technology-driven Pacific: Fastest GrowthThe Asia Pacific region is expected to experience the fastest growth, fueled by booming IT infrastructure in emerging economies like China and India. The region's thriving consumer electronics industry, coupled with the presence of global players like Toshiba, Micron, and Samsung, drives market expansion. For instance, in June 2023, Micron Technology announced a US$825 million investment to build DRAM and NAND assemblies, including SSDs, in Gujarat, India, highlighting the region's growing Benefits of this Report: Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments. Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy. Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments. Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment. Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises. Report Coverage: Historical data from 2022 to 2024 & forecast data from 2025 to 2030 Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis Competitive Positioning, Strategies, and Market Share Analysis Revenue Growth and Forecast Assessment of segments and regions including countries Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $35.55 Billion Forecasted Market Value (USD) by 2030 $72.66 Billion Compound Annual Growth Rate 15.3% Regions Covered Global Company Profiling (Strategies, Products, Financial Information, and Key Developments) Intel Corporation SAMSUNG Kingston Technology Europe Co LLP Western Digital Corporation Micron Technology, Inc. SK hynix Inc. Seagate Technology LLC KIOXIA Corporation ATP Electronics, Inc. Segmentation: By Interface Type SATA SAS Fibre Channel ATA/IDE By End-User Industry Automotive Aerospace and Defense Medical Consumer Electronics Others By Geography North America USA Canada Mexico South America Brazil Argentina Others Europe Germany France United Kingdom Spain Others Middle East and Africa Saudi Arabia UAE Others Asia Pacific China Japan South Korea India Indonesia Thailand Taiwan Others For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Solid State Drive Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Jake Bengtson Joins Striim as VP of AI Solutions to Lead the Next Phase of AI-Ready Data Infrastructure
PALO ALTO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Striim, a recognized leader in real-time data integration and intelligence, today announced the appointment of Jake Bengtson as Vice President of AI Solutions. With a decade of experience building and deploying AI strategies at enterprise scale, Bengtson will play a central role in helping customers apply real-time data to real-world AI use cases. Bengtson brings more than a decade of deep AI expertise to Striim's leadership team, with a proven track record of building enterprise-scale AI initiatives across energy, utilities, and data-intensive industries. Most recently at Cloudera, he helped shape the go-to-market strategy for AI, machine learning, and trusted AI solutions. This experience will be pivotal as Striim accelerates its AI roadmap. 'Striim is already doing what most companies are still trying to figure out—delivering real-time, trustworthy data at scale,' said Jake Bengtson, VP of AI Solutions at Striim. 'Joining a team that's not just talking about AI readiness, but enabling it every day, is what made this an easy decision. I'm excited to help push the boundaries even further.' His appointment reflects Striim's continued investment in delivering innovative, real-world, and scalable AI outcomes — and the company's belief that real-time data is the foundation for trustworthy AI at enterprise scale. Specifically, Bengtson will help drive impact in the following areas: Strategic depth: A more integrated AI go-to-market strategy that connects Striim's real-time AI and streaming capabilities to the priorities of technical decision-makers, from heads of data to AI engineering teams Industry alignment: Focused solution development for highly regulated sectors like healthcare, energy, and financial services—where accuracy, explainability, and data freshness are non-negotiable AI application innovation: Bridge real-world AI and data requirements in areas such as GenAI, LLM fine-tuning, Vector stores, and Agentic AI with Product R&D initiatives and Roadmap. Market leadership: Evangelism—and expansion—of Striim's position as the trusted backbone for real-time AI workloads, reinforcing our role in the modern enterprise data stack Customer alignment: Tighter feedback loops with AI-forward customers to ensure product investments directly support production-grade ML pipelines, observability, and governance at scale 'We're seeing growing demand from customers who want to move faster with AI—and they're choosing Striim because we're built for that pace,' said Nadim Antar, Chief Revenue Officer at Striim. 'Jake brings deep experience in scaling enterprise AI efforts, and we're thrilled to have him on board as we help more organizations turn real-time data into real business outcomes.' ABOUT STRIIM, INC. Striim pioneers real-time intelligence for AI by unifying data across clouds, applications, and databases via a fully managed, SaaS-based platform. Striim's platform, optimized for modern cloud data warehouses, transforms relational and unstructured data into AI-ready insights instantly with advanced analytics and ML frameworks, enabling swift business action. Striim leverages its expertise in real-time data integration, streaming analytics, and database replication, including industry-leading Oracle, PostgreSQL, MongoDB CDC technology, to achieve sub-second latency in processing over 100 billion daily events for ML analytics and proactive decision-making. To learn more, visit Media Contact: Dianna Spring, Vice President of Marketing at StriimPhone: (650) 241-0680 ext. 354Email: press@ Source: Striim, nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Associated Press
an hour ago
- Associated Press
CorTec Announces Neurotech Milestone: First Human Implantation of a Brain-Computer Interface made in Germany
FREIBURG, Germany, July 29, 2025 (GLOBE NEWSWIRE) -- CorTec GmbH, a pioneer in active implantable medical technologies, today announced the first human implantation of its proprietary BCI system, Brain Interchange™, marking a pivotal advance in translating laboratory research into real-world clinical applications. The procedure took place in late July at Harborview Medical Center (Seattle) under an FDA Investigational Device Exemption (IDE). Led by Principal Investigator Jeffrey G. Ojemann, MD, from the University of Washington School of Medicine in Seattle and Co PI Professor Steven C. Cramer from the University of California, Los Angeles, this trial will gather initial safety data and evaluate whether direct cortical electrical stimulation can enhance upper-limb motor recovery in stroke patients. The study is funded by the National Institutes of Health (NIH). 'We're thrilled to share that the implantation procedure was a success and, most importantly, the patient is in good condition and recovering well from the surgery. We're incredibly grateful for this initial outcome in our first study participant. Both the therapeutic strategy and the technology we are using are entirely novel. While we proceed with careful optimism, the potential benefits for patients are promising,' commented Jeffrey G. Ojemann, MD, Vice Chair and Professor of Neurological Surgery, University of Washington School of Medicine. This novel approach offers highly precise and personalized treatment for neurological conditions. The implant system continuously records brain activity, instantly interpreting signals and delivering targeted electrical stimulation in real time to enhance neuroplasticity, the brain's ability to reorganize neural networks. The study explores whether this can help the brain relearn lost functions, thereby accelerating and improving rehabilitation of patients. 'The first implantation of our BCI marks a milestone for European medical neurotechnology and underscores CorTec's emergence as Germany's first implantable BCI developer, ready to compete on the global stage,' said Dr. Frank Desiere, CEO of CorTec. 'Building on our extensive experience in developing advanced components and active implantable systems, our proprietary cutting-edge BCI system is now entering human clinical testing, aiming to help people affected by neurological diseases recover lost function and enhance their quality of life. We are proud of this new era of innovation and are committed to expanding the possibilities of neurotechnology to improve outcomes for patients.' Today in the US and Europe alone, 1.7 million people annually have a stroke that frequently involves loss of upper limb function. While physical therapy alone can help many patients regain function, it is sometimes not sufficient. Patients with a BCI may benefit from neuroplasticity-inducing stimulation during their rehabilitation. Regaining control of their upper limbs would enable patients to be more independent and have a better quality of life. 'This breakthrough opens the door to therapies that were once unimaginable,' added Dr. Martin Schuettler, CTO of CorTec. 'For the first time, our BCI system connects wirelessly to external hardware – no cables, no physical links. This approach is part of the transformation of neurological therapies worldwide, built on a technology platform that can be tailored to multiple neurological conditions, delivering real-time, patient-specific treatment. I'm incredibly proud of our team and our partners, in particular Jeffrey G. Ojemann and Jeffrey Herron of UW Medicine, who turned years of research into real hope for patients.' About CorTec CorTec GmbH, founded in 2010 in Freiburg, Germany is a pioneer in active implantable technologies and brain-computer interface (BCI) systems. The company is an established partner for medical device development and manufacturing for advanced components and active implantable systems. Its cutting-edge technologies drive innovation across the neurotechnology landscape—enabling researchers, clinicians, and industry leaders to unlock new clinical frontiers and engineer next-generation medical devices precisely tailored to targeted therapeutic indications. At the heart of CorTec's portfolio is the Brain InterchangeTM System, a fully implantable, wireless investigational device capable of long-term sensing and adaptive stimulation of neural tissue. The system is designed as a versatile platform to accelerate the development of novel, personalized neuromodulation therapies. CorTec's growth is supported by a strong network of strategic investors, including High-Tech Gruenderfonds, KfW, K&SW Invest, LBBW Venture Capital, Mangold Invest, M-Invest and Santo Venture Capital GmbH. For more information, visit Disclaimer: The research reported in this publication is supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number UH3NS121565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
